Chiasma (NASDAQ:CHMA) Lowered to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Chiasma (NASDAQ:CHMA) from a buy rating to a hold rating in a research report report published on Wednesday morning, Zacks.com reports.

According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “

Other research analysts have also issued reports about the company. HC Wainwright lowered Hydrogenics from a buy rating to a neutral rating in a research report on Friday, June 28th. Cantor Fitzgerald set a $18.00 price target on Chiasma and gave the stock a buy rating in a research note on Friday, June 28th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Chiasma has a consensus rating of Buy and an average price target of $12.94.

Shares of CHMA stock opened at $6.44 on Wednesday. Chiasma has a fifty-two week low of $1.20 and a fifty-two week high of $8.29. The business has a 50-day moving average price of $7.40.

Chiasma (NASDAQ:CHMA) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Sell-side analysts anticipate that Chiasma will post -1.14 earnings per share for the current year.

In other news, Director Roni Mamluk sold 10,000 shares of the company’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $5.31, for a total transaction of $53,100.00. Following the completion of the sale, the director now owns 10,000 shares in the company, valued at approximately $53,100. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.20% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new stake in shares of Chiasma during the 4th quarter worth about $41,000. Acadian Asset Management LLC boosted its stake in shares of Chiasma by 99.1% during the 4th quarter. Acadian Asset Management LLC now owns 22,647 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 11,273 shares in the last quarter. Tibra Equities Europe Ltd bought a new stake in shares of Chiasma during the 1st quarter worth about $200,000. Deutsche Bank AG boosted its stake in shares of Chiasma by 27.8% during the 4th quarter. Deutsche Bank AG now owns 78,198 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 16,996 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Chiasma by 20.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 97,644 shares of the biotechnology company’s stock worth $304,000 after acquiring an additional 16,658 shares in the last quarter. Institutional investors own 62.78% of the company’s stock.

About Chiasma

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Further Reading: Why investors pay attention to retained earnings

Get a free copy of the Zacks research report on Chiasma (CHMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.